Farxiga OK'd for All EF; Older Donor Hearts; Cardiologist Arrested for Deaths

(MedPage Today) -- FDA gave expanded approval to the SGLT-2 inhibitor dapagliflozin (Farxiga) for preventing cardiovascular death, heart failure hospitalization, and urgent heart failure visits in all patients with heart failure regardless of ejection...
Source: MedPage Today Cardiovascular - Category: Cardiology Source Type: news